Southend University Hospital NHS
NHS Foundation Trust

October 2011

1. Thanks for your reply, would it be possible to obtain information on biologic usage from your pharmacy systems, not split by disease?

Please find below your completed table with the information we hold on biologics usage.

Biologics	Jan 2011	Feb 2011	Mar 2011	Apr 2011	May 2011	Jun 2011	Jul 2011	Aug 2011	Sep 2011	Oct 2011
Abatacept [Orencia]	0	0	0	0	0	0	0	0	0	0
Adalimumab [Humira]	28	20	16	28	14	16	2	35	26	22
Anakinra [Kineret]	1	0	1	0	0	0	0	0	0	1
Certolizumab [Cimzia]	0	0	27	6	0	6	5	32	4	7
Etanercept [Enbrel]	0	0	0	0	0	0	0	0	0	0
Infliximab [Remicade]	124	155	149	134	132	269	57	176	129	181
Rituximab [Mabthera]	91	96	134	83	96	101	102	121	151	140
Tocilizumab [Ro Actemra]	15	12	12	12	10	12	23	21	20	15
Ustekinumab [Stelara]	0	0	0	0	0	0	0	0	0	0
Others										